Skip to main content
Clinical Trials/IRCT2012092910933N1
IRCT2012092910933N1
Completed
Phase 3

Evaluating the effect of low dose vs moderate dose clofibrate on decreasing serum bilirubin in healthy full term neonates

Hamadan University of Medical Sciences0 sites132 target enrollmentTBD

Overview

Phase
Phase 3
Intervention
Not specified
Conditions
eonatal jaundice.
Sponsor
Hamadan University of Medical Sciences
Enrollment
132
Status
Completed
Last Updated
8 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
8 years ago
Study Type
Interventional
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • Inclusion criteria included: (a) age of 2 to 29 days; (b) full term newborn (gestational age between 38 to 40 weeks); (c) weight of 2500 to 4000 gr; having indirect hyperbilirubinemia (TSB\>16 mg/dl) ; (d) absence of hemolysis, ABO or Rh incompatibility; (e) negative coomb’s test; (f) reticulocyte count less than 5%.
  • Exclusion criteria : The neonates with sign of sepsis, electrolyte impairment, any congenital anomalies or disease, seizure, formula feeding, hemolytic disease and those who need exchange transfusion were excluded from the study.

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

Not specified

Similar Trials